chlorobenzene-ammonia

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: chlorobenzene-ammonia
• 英文别名: Azane;chlorobenzene
• 化学式: C₆H₅Cl*H₃N
• 分子量: 129.589
• InChiKey: FXICHSQUUNYSCS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  chlorobenzene-ammonia 生成 anilinium
  参考文献：
  名称：

  Nucleophilic substitution within the photoionized van der Waals complex: generation of C6H5NH3+ from C6H5Cl-NH3

  摘要：

  DOI：

  10.1021/ja00229a062
• 作为产物：
  描述：

  氯苯 在 氨 作用下， 生成 chlorobenzene-ammonia
  参考文献：
  名称：

  Nucleophilic substitution within the photoionized van der Waals complex: generation of C6H5NH3+ from C6H5Cl-NH3

  摘要：

  DOI：

  10.1021/ja00229a062

文献信息

• AROMATIC RING FUSED TRIAZINE DERIVATIVES AND USES THEREOF
  申请人：Zhao Linxiang

  公开号：US20110183972A1

  公开（公告）日：2011-07-28

  The invention belongs to pharmaceutical field. The invention relates to the compounds according to Formula I, including their optically active forms, pharmaceutically acceptable salts or hydrates, and the pharmaceutical composition comprising thereof as active ingredient; uses in the preparation of vascular endothelial growth factor receptor tyrosine kinase inhibitors, and uses in the preparation of medicament for the treatment and/or prevention of cancer.

  本发明属于药物领域。本发明涉及根据公式I的化合物，包括它们的光学活性形式、药物可接受的盐或水合物，以及包含它们作为活性成分的药物组合物；用于制备血管内皮生长因子受体酪氨酸激酶抑制剂的使用，以及用于制备治疗和/或预防癌症的药物的使用。
• [EN] ENANTIOMERIC RESOLUTION METHOD<br/>[FR] PROCÉDÉ DE RÉSOLUTION ÉNANTIOMÉRIQUE
  申请人：PULMAGEN THERAPEUTICS INFLAMMATION LTD

  公开号：WO2011015868A1

  公开（公告）日：2011-02-10

  A method for the preparation of pioglitazone O,O'-dibenzoyl-L-tartrate wherein the content by weight of pioglitazone consists of at least 95 % by weight of the 5R enantiomer and less than 5 % of the 5S enantiomer, which method comprises: (1a) adding seed crystals of 5R- pioglitazone O,O'-dibenzoyl-l-tartrate to a rnethanol-water solution of racemic pioglitazone hydrochloride and O,O'-dibenzoyI-L-tartaric acid, thereby precipitating pioglitazone O,O'- dibenzoyl-L-tartrate;(1b) recovering said precipitate from step (1a); (1c) forming a solution of the precipitate from step (1b) in a solvent mixture of methanol, acid and water and mixing into to the resultant solution seed crystals of 5R-pioglitazone O,O'-dibenzoyl-L-tartrate, thereby precipitating pioglitazone O,O'-dibenzoyl-L-tartrate; (1d) recovering said precipitate from step (1c); (1e) repeating steps (1c) and (1d), the recovered product being the desired pioglitazone O,O'-dibenzoy! tartrate wherein the content by weight of pioglitazone consists of at least 95 % by weight of the 5R enantiomer and less than 5 % of the 5S enantiomer. Also disclosed is a modification of the method in which step 1(e) is omitted.

  一种制备吡格列酮O，O'-双苯甲酰-L-酒石酸盐的方法，其中吡格列酮的重量含量至少为其5R对映体的95%重量，5S对映体的含量少于5%，该方法包括：（1a）将5R-吡格列酮O，O'-双苯甲酰-L-酒石酸晶种加入到外消旋吡格列酮盐酸盐和O，O'-双苯甲酰-L-酒石酸的甲醇-水溶液中，从而沉淀吡格列酮O，O'-双苯甲酰-L-酒石酸盐；（1b）从步骤（1a）中回收所述沉淀物；（1c）在甲醇、酸和水的溶剂混合物中形成步骤（1b）中的沉淀物的溶液，并将5R-吡格列酮O，O'-双苯甲酰-L-酒石酸晶种混入到所得溶液中，从而沉淀吡格列酮O，O'-双苯甲酰-L-酒石酸盐；（1d）从步骤（1c）中回收所述沉淀物；（1e）重复步骤（1c）和（1d），回收的产品即为所需的吡格列酮O，O'-双苯甲酰-L-酒石酸盐，其中吡格列酮的重量含量至少为其5R对映体的95%重量，5S对映体的含量少于5%。还揭示了一种修改该方法的步骤，其中省略了步骤1（e）。
• Thia-tetraazaacenaphthylene kinase inhibitors
  申请人：Battista A. Kathleen

  公开号：US20070265264A1

  公开（公告）日：2007-11-15

  The present invention is directed to novel thia-tetraazaacenaphthylene compounds of Formula (I): and pharmaceutically acceptable forms thereof and their synthesis and use as inhibitors of ATP-protein kinase interactions.

  本发明涉及公式(I)的新型硫代四氮杂蒽化合物及其药学上可接受的形式，以及它们的合成和用作ATP-蛋白激酶相互作用抑制剂的用途。
• RESPIRATORY DISEASE TREATMENT
  申请人：Finch Harry

  公开号：US20110053986A1

  公开（公告）日：2011-03-03

  There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.

  提供了一种适用于肺部吸入的药物组合物，该组合物包括一种格列吡嗪，例如派格列酮或罗格列酮，以及一种或多种药用载体和/或赋形剂，其中该组合物的格列吡嗪含量由至少95%的5R对映体和少于5%的5S对映体组成。还提供了使用和工具包。
• Respiratory Disease Treatment
  申请人：FINCH Harry

  公开号：US20120264787A1

  公开（公告）日：2012-10-18

  There is provided a pharmaceutical composition that is adapted for pulmonary administration by inhalation, which composition comprises a glitazone, such as pioglitazone or rosiglitazone, and one or more pharmaceutically acceptable carriers and/or excipients, and wherein the glitazone content of the composition consists of at least 95% by weight of the 5R enantiomer and less than 5% by weight of the 5S enantiomer. There is also provided a use and kit.

  提供了一种适用于通过吸入进行肺部给药的制剂，该制剂包括一种glitazone，例如pioglitazone或rosiglitazone，以及一种或多种药学上可接受的载体和/或赋形剂，其中该制剂中的glitazone含量由至少95%的5R对映体和少于5%的5S对映体组成。还提供了一种用途和工具包。